Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
NCT ID: NCT05297240
Last Updated: 2022-08-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
170 participants
Study Classification
OBSERVATIONAL
Study Start Date
2022-03-24
Study Completion Date
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The proposal of this study is to retrospectively analyze the experience with belantamab mafodotin monotherapy in patients with RRMM included in the compassionate use or in the expanded access program in Spain between November 2019 and June 2021.
The focus of the study will be on the estimation of the magnitude of the treatment effect as assessed by the overall response rate (ORR), duration of response (DOR), progression free survival (PFS), overall survival (OS), and the safety of single agent belantamab mafodotin in patients with RRMM.
Subjects may receive treatment until progression. Myeloma disease status will be evaluated locally for response and progression per International Myeloma Working Group (IMWG) criteria from cycle 1 day 1 until confirmed progressive disease, death, unacceptable toxicity, or lost to follow-up (whichever occurs first).
The focus of the study will be on the estimation of the magnitude of the treatment effect as assessed by the overall response rate (ORR), duration of response (DOR), progression free survival (PFS), overall survival (OS), and the safety of single agent belantamab mafodotin in patients with RRMM.
Subjects may receive treatment until progression. Myeloma disease status will be evaluated locally for response and progression per International Myeloma Working Group (IMWG) criteria from cycle 1 day 1 until confirmed progressive disease, death, unacceptable toxicity, or lost to follow-up (whichever occurs first).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy
NCT05393024
Multiple Myeloma
COMPLETED
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT05986682
Multiple Myeloma
COMPLETED
Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT05117008
Refractory Multiple Myeloma
Relapse Multiple Myeloma
TERMINATED
PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
NCT07217119
Multiple Myeloma
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
NCT05065047
Multiple Myeloma
TERMINATED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The proposal of this study is to retrospectively analyze the experience with belantamab mafodotin monotherapy in patients with RRMM included in the compassionate use or in the expanded access program in Spain between November 2019 and June 2021.
Subjects may receive treatment until progression. Myeloma disease status will be evaluated locally for response and progression per International Myeloma Working Group (IMWG) criteria from cycle 1 day 1 until confirmed progressive disease, death, unacceptable toxicity, or lost to follow-up (whichever occurs first).
The study has the following objectives:
Primary objective
\- The primary objective of this study is to evaluate the efficacy of belantamab mafodotin in terms of overall response, and the different response categories when administered as a single agent in patients with RRMM.
Secondary objectives:
* Describe the safety and tolerability of single-agent belantamab mafodotin.
* The overall incidence of ophthalmologic complications.
* Estimate duration of response (DOR).
* Estimate time to response (TTR).
* Estimate time to next treatment (TTNT).
* Estimate progression-free survival (PFS) and overall survival (OS).
* Type of treatment administered after single-agent belantamab mafodotin and estimate PFS2.
Subjects may receive treatment until progression. Myeloma disease status will be evaluated locally for response and progression per International Myeloma Working Group (IMWG) criteria from cycle 1 day 1 until confirmed progressive disease, death, unacceptable toxicity, or lost to follow-up (whichever occurs first).
The study has the following objectives:
Primary objective
\- The primary objective of this study is to evaluate the efficacy of belantamab mafodotin in terms of overall response, and the different response categories when administered as a single agent in patients with RRMM.
Secondary objectives:
* Describe the safety and tolerability of single-agent belantamab mafodotin.
* The overall incidence of ophthalmologic complications.
* Estimate duration of response (DOR).
* Estimate time to response (TTR).
* Estimate time to next treatment (TTNT).
* Estimate progression-free survival (PFS) and overall survival (OS).
* Type of treatment administered after single-agent belantamab mafodotin and estimate PFS2.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_ONLY
Study Time Perspective
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belantamab mafodotin
At least one dose of belantamab mafodotin as part of the compassionate use or the expanded access program in Spain between November 2019 and June 2021.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Reception of at least one dose of belantamab mafodotin as part of the compassionate use or the expanded access program in Spain between November 2019 and June 2021
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Sponsor Role
collaborator
PETHEMA Foundation
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Javier de la Rubia
Role: PRINCIPAL_INVESTIGATOR
Hospital La Fe de Valencia
Adrián Alegre
Role: PRINCIPAL_INVESTIGATOR
Hospital La Princesa (Madrid)
María Victoria Mateos
Role: PRINCIPAL_INVESTIGATOR
Hospital Clínico, Salamanca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
H. Universitario de Albacete
Albacete, , Spain
Site Status
RECRUITING
H. Doctor José Molina Orosa
Arrecife, , Spain
Site Status
RECRUITING
H. San Agustín
Avilés, , Spain
Site Status
RECRUITING
H. Ntra. Señora Sonsoles
Ávila, , Spain
Site Status
RECRUITING
H. Clinic de Barcelona
Barcelona, , Spain
Site Status
RECRUITING
H. Moises Broggi
Barcelona, , Spain
Site Status
RECRUITING
H. Vall d' Hebron
Barcelona, , Spain
Site Status
RECRUITING
H. Basurto
Bilbao, , Spain
Site Status
RECRUITING
H. Cruces
Bilbao, , Spain
Site Status
RECRUITING
H. Calahorra
Calahorra, , Spain
Site Status
RECRUITING
H. Reina Sofía
Córdoba, , Spain
Site Status
RECRUITING
H. General Elche
Elche, , Spain
Site Status
RECRUITING
H. Fuenlabrada
Fuenlabrada, , Spain
Site Status
RECRUITING
H. Galdakao
Galdakao, , Spain
Site Status
RECRUITING
H. Francisco de Borja
Gandia, , Spain
Site Status
RECRUITING
ICO Girona
Girona, , Spain
Site Status
RECRUITING
H. Un. Virgen de las Nieves
Granada, , Spain
Site Status
RECRUITING
H. Un. Guadalajara
Guadalajara, , Spain
Site Status
RECRUITING
H. Juan Ramón Jiménez
Huelva, , Spain
Site Status
RECRUITING
H. Universitario de Jaén
Jaén, , Spain
Site Status
RECRUITING
H. Un. Doctor Negrín
Las Palmas de Gran Canaria, , Spain
Site Status
RECRUITING
H. Severo Ochoa
Leganés, , Spain
Site Status
RECRUITING
H. León
León, , Spain
Site Status
RECRUITING
H. San Pedro
Logroño, , Spain
Site Status
RECRUITING
H. Un. Lucus Augusti
Lugo, , Spain
Site Status
RECRUITING
Fundación Jiménez Díaz
Madrid, , Spain
Site Status
RECRUITING
H. Gregorio Marañón
Madrid, , Spain
Site Status
RECRUITING
H. Moncloa
Madrid, , Spain
Site Status
RECRUITING
H. Ruber Juan Bravo
Madrid, , Spain
Site Status
RECRUITING
H. Un. Doce de Octubre
Madrid, , Spain
Site Status
RECRUITING
H. Un. Infanta Sofía
Madrid, , Spain
Site Status
RECRUITING
H. Un. La Paz
Madrid, , Spain
Site Status
RECRUITING
H. Un. La Princesa
Madrid, , Spain
Site Status
RECRUITING
H. Un. Puerta del Hierro
Madrid, , Spain
Site Status
RECRUITING
H. Un. Quirón Salud
Madrid, , Spain
Site Status
RECRUITING
H.M. Sanchinarro
Madrid, , Spain
Site Status
RECRUITING
Hospital Clínico San Carlos
Madrid, , Spain
Site Status
RECRUITING
Hospital Universitario Henares
Madrid, , Spain
Site Status
RECRUITING
Hospital Universitario Ramón y Cajal
Madrid, , Spain
Site Status
RECRUITING
H. Virgen de la Victoria
Málaga, , Spain
Site Status
RECRUITING
H. Rey Juan Carlos
Móstoles, , Spain
Site Status
RECRUITING
H. Morales Meseguer
Murcia, , Spain
Site Status
RECRUITING
H. Un. Virgen de la Arrixaca
Murcia, , Spain
Site Status
RECRUITING
H. Universitario Central Asturias
Oviedo, , Spain
Site Status
RECRUITING
H. Son Llatzer
Palma de Mallorca, , Spain
Site Status
RECRUITING
H. Un. Son Espases
Palma de Mallorca, , Spain
Site Status
RECRUITING
H. Montecelo
Pontevedra, , Spain
Site Status
RECRUITING
H. Un. Salamanca
Salamanca, , Spain
Site Status
RECRUITING
H. Un. Canarias
Santa Cruz de Tenerife, , Spain
Site Status
RECRUITING
H. Un. Marqués de Valdecilla
Santander, , Spain
Site Status
RECRUITING
H. General Segovia
Segovia, , Spain
Site Status
RECRUITING
H. Un. Virgen de Valme
Seville, , Spain
Site Status
RECRUITING
H. Virgen del Rocío
Seville, , Spain
Site Status
RECRUITING
H. Mutua Terrasa
Terrassa, , Spain
Site Status
RECRUITING
H. Ntra. Señora del Prado
Toledo, , Spain
Site Status
RECRUITING
H. Un. Torrejón
Torrejón de Ardoz, , Spain
Site Status
RECRUITING
H. Un. Dr. Peset
Valencia, , Spain
Site Status
RECRUITING
H. Universitario de la Fe
Valencia, , Spain
Site Status
RECRUITING
H. Universitario de Valladolid
Valladolid, , Spain
Site Status
RECRUITING
H. Clinico Un. Lozano Blesa
Zaragoza, , Spain
Site Status
RECRUITING
H. Miguel Servet
Zaragoza, , Spain
Site Status
RECRUITING
H. Royo Villanova
Zaragoza, , Spain
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Spain
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Juan Ramón Romero Macías
Role: primary
Víctor Alfonso Ferrandez
Role: primary
Walter Javier Zambrano
Role: primary
Abelardo Bárez
Role: primary
Ana Triguero
Role: primary
María Elena María Elena Cabezudo/Gabriela Bustamante
Role: primary
Mercedes Gironella
Role: primary
José Antonio Márquez
Role: primary
Xavier Martín
Role: primary
Estefanía Ruiz
Role: primary
Margarita Fernández de la Mata
Role: primary
Venancio Conesa
Role: primary
Amaia López
Role: primary
Eukene Gainza
Role: primary
María Ángeles Ruiz
Role: primary
Yolanda González
Role: primary
Esther Clavero
Role: primary
Alejandro Vázquez Ramo
Role: primary
Juan Francisco Domínguez
Role: primary
Magdalena Anguita
Role: primary
Alexia Alexia Suarez Cabrera
Role: primary
Rosalía Riaza
Role: primary
Fernando Escalante
Role: primary
Montserrat Hernández
Role: primary
Esperanza Lavilla
Role: primary
Elena Prieto
Role: primary
Cristina Encinas
Role: primary
Concha Alaez Usón
Role: primary
Aranzazu Alonso Alonso
Role: primary
Joaquin Martínez
Role: primary
Eugenio Giménez
Role: primary
Ana López de la Guía
Role: primary
Gonzalo Benzo
Role: primary
Rafael Ríos Tamayo
Role: primary
Carmen Martínez Chamorro
Role: primary
Laura Llorente
Role: primary
Cristina Pérez
Role: primary
Cristina Muñoz
Role: primary
Maria Jesús Blanchard
Role: primary
Ricarda García
Role: primary
Alberto Eterio Velasco
Role: primary
Felipe de Arriba
Role: primary
Valentín Cabañas
Role: primary
Ángel Ramirez Payer
Role: primary
Raquel del Campo García
Role: primary
José María Sánchez Raga
Role: primary
Ana Maria Dios Loureiro
Role: primary
Ramón García Sanz
Role: primary
Álvaro Bienert García
Role: primary
Maria Aranzazu Bermúdez
Role: primary
Aranzazu García
Role: primary
Eduardo Ríos
Role: primary
Estrella Carrillo
Role: primary
Josep Maria Martí
Role: primary
María Dolores Martínez Moya
Role: primary
Ana Morales
Role: primary
Ana García Feria
Role: primary
Rafael Andreu La Piedra
Role: primary
Alfonso García de Coca
Role: primary
Luis Palomera
Role: primary
Araceli Rubio
Role: primary
Vicente Carrasco
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011 Mar 17;364(11):1046-60. doi: 10.1056/NEJMra1011442. No abstract available.
Reference Type
BACKGROUND
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014 May;28(5):1122-8. doi: 10.1038/leu.2013.313. Epub 2013 Oct 25.
Reference Type
BACKGROUND
Zanwar S, Abeykoon JP, Kapoor P. Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. Curr Hematol Malig Rep. 2019 Apr;14(2):70-82. doi: 10.1007/s11899-019-00500-4.
Reference Type
BACKGROUND
Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. J Natl Compr Canc Netw. 2019 Oct 1;17(10):1154-1165. doi: 10.6004/jnccn.2019.0049.
Reference Type
BACKGROUND
Hoyos V, Borrello I. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies. Blood. 2016 Sep 29;128(13):1679-87. doi: 10.1182/blood-2016-05-636357. Epub 2016 Aug 9.
Reference Type
BACKGROUND
Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev. 2011 Nov;244(1):115-33. doi: 10.1111/j.1600-065X.2011.01067.x.
Reference Type
BACKGROUND
Frigyesi I, Adolfsson J, Ali M, Christophersen MK, Johnsson E, Turesson I, Gullberg U, Hansson M, Nilsson B. Robust isolation of malignant plasma cells in multiple myeloma. Blood. 2014 Feb 27;123(9):1336-40. doi: 10.1182/blood-2013-09-529800. Epub 2014 Jan 2.
Reference Type
BACKGROUND
Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, Hoang B, Tunstead J, Christie AL, Kung AL, Richardson P, Munshi NC, Anderson KC. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014 May 15;123(20):3128-38. doi: 10.1182/blood-2013-10-535088. Epub 2014 Feb 25.
Reference Type
BACKGROUND
Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, Delon C, Latzko M, Gianotti R, Luoend R, Murr R, Hosse RJ, Harnisch LJ, Bacac M, Fauti T, Klein C, Zabaleta A, Hillengass J, Cavalcanti-Adam EA, Ho AD, Hundemer M, San Miguel JF, Strein K, Umana P, Hose D, Paiva B, Vu MD. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2.
Reference Type
BACKGROUND
Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004 Apr 15;103(8):3148-57. doi: 10.1182/blood-2003-06-1984. Epub 2003 Dec 4.
Reference Type
BACKGROUND
Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, Cea M, Cagnetta A, Wen K, van Eenennaam H, van Elsas A, Qiu L, Richardson P, Munshi N, Anderson KC. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016 Jun 23;127(25):3225-36. doi: 10.1182/blood-2016-01-691162. Epub 2016 Apr 28.
Reference Type
BACKGROUND
Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA, Crowley J, Chen H, Berenson JR. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012 Sep;158(6):727-38. doi: 10.1111/j.1365-2141.2012.09241.x. Epub 2012 Jul 18.
Reference Type
BACKGROUND
Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, Fieles WE, Tunstead J, McCahon L, Germaschewski FM, Mayes PA, Craigen JL, Rodriguez-Justo M, Yong KL. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol. 2016 Sep;174(6):911-22. doi: 10.1111/bjh.14145. Epub 2016 Jun 17.
Reference Type
BACKGROUND
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD Jr, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018 Dec;19(12):1641-1653. doi: 10.1016/S1470-2045(18)30576-X. Epub 2018 Nov 12.
Reference Type
BACKGROUND
Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortum KM, Rodriguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16.
Reference Type
BACKGROUND
Lonial S, Lee HC, Badros A, et al. Cancer. 2021 Jul 27. doi: 10.1002/cncr.33809. Online ahead of print. PMID: 34314018
Reference Type
BACKGROUND
Shah JJ, Abonour R, Gasparetto C, Hardin JW, Toomey K, Narang M, Srinivasan S, Kitali A, Zafar F, Flick ED, Rifkin RM. Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes. Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):575-583.e2. doi: 10.1016/j.clml.2017.06.013. Epub 2017 Jun 17.
Reference Type
BACKGROUND
Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A, Huang H, Richardson P. Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):8-17.e16. doi: 10.1016/j.clml.2019.09.625. Epub 2019 Oct 10.
Reference Type
BACKGROUND
Fiala M, et al. The real-world characteristics and outcomes of newly diagnosed myeloma patients ineligible for clinical trials. Clin. Lymphoma Myeloma Leuk. 2017;17:e55-e56
Reference Type
BACKGROUND
Hungria VTM, et al. Real-world (RW) multiple myeloma (MM) patients (Pts) remain under-represented in clinical trials based on standard laboratory parameters and baseline characteristics: analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study. Blood. 2019;134:1887a
Reference Type
BACKGROUND
Klausen TW, Gregersen H, Abildgaard N, Andersen NF, Frolund UC, Gimsing P, Helleberg C, Vangsted AJ. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. Leukemia. 2019 Feb;33(2):546-549. doi: 10.1038/s41375-018-0272-0. Epub 2018 Sep 28. No abstract available.
Reference Type
BACKGROUND
Bergin K, McQuilten Z, Moore E, Wood E, Spencer A. Myeloma in the Real World: What Is Really Happening? Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):133-144.e1. doi: 10.1016/j.clml.2016.12.002. Epub 2016 Dec 26.
Reference Type
BACKGROUND
Song X, Cong Z, Wilson K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin. 2016;32(1):95-103. doi: 10.1185/03007995.2015.1105202. Epub 2015 Nov 20.
Reference Type
BACKGROUND
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GEM-RELAMAB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04126200
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
NCT05581875
NOT_YET_RECRUITING
PHASE1/PHASE2
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
NCT05060627
RECRUITING
PHASE1/PHASE2
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
NCT05064358
ACTIVE_NOT_RECRUITING
PHASE2
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04177823
COMPLETED
PHASE1
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
NCT07150104
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
NCT06655818
TERMINATED
PHASE1/PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
NCT07084896
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
NCT07150091
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
NCT04802356
ACTIVE_NOT_RECRUITING
PHASE2
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
NCT05874193
NOT_YET_RECRUITING
PHASE2
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
NCT06160609
TERMINATED
PHASE1/PHASE2
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07227311
NOT_YET_RECRUITING
PHASE2
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT04808037
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
NCT04091126
ACTIVE_NOT_RECRUITING
PHASE1
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
NCT04398745
ACTIVE_NOT_RECRUITING
PHASE1
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
NCT03525678
COMPLETED
PHASE2
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
NCT05847569
RECRUITING
PHASE2
A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
NCT05461209
WITHDRAWN
PHASE3
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
NCT05280275
RECRUITING
PHASE1/PHASE2
A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis
NCT04617925
COMPLETED
PHASE2
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
NCT05922501
RECRUITING
PHASE2